N-alpha-acetyltransferase 50, NatE catalytic subunit
Homo sapiens
当前结构中的状态
| Assembly | 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与共同组分 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|
| 1 | 蛋白异源复合物 异源复合物 蛋白 × 2 PDB 声明:dimeric(2) 与蛋白拷贝数一致 | 链 A; UniProt 1–169 | 未记录 | hnRNP F × 1 COA COENZYME A × 1 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, HANGING DROP;pH 5;273 K;well solution: 16% PEG 8000, 20% glycerol, 40mM potassium phosphate (monobasic), pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 273K | 分辨率 2.75 Å R-free 0.254 |
| 2 | 蛋白异源复合物 异源复合物 蛋白 × 2 PDB 声明:dimeric(2) 与蛋白拷贝数一致 | 链 B; UniProt 1–169 | 未记录 | hnRNP F × 1 COA COENZYME A × 1 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, HANGING DROP;pH 5;273 K;well solution: 16% PEG 8000, 20% glycerol, 40mM potassium phosphate (monobasic), pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 273K | 分辨率 2.75 Å R-free 0.254 |
| 3 | 蛋白异源复合物 异源复合物 蛋白 × 2 PDB 声明:dimeric(2) 与蛋白拷贝数一致 | 链 C; UniProt 1–169 | 未记录 | hnRNP F × 1 COA COENZYME A × 1 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, HANGING DROP;pH 5;273 K;well solution: 16% PEG 8000, 20% glycerol, 40mM potassium phosphate (monobasic), pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 273K | 分辨率 2.75 Å R-free 0.254 |
数据库中的同蛋白其他状态
以下每一行都是同一 UniProt 蛋白在另一个 PDB 条目中的 biological assembly, “相对当前条目”直接指出证据层面的不同;没有差异标签表示当前已读取字段一致。
| 其他 PDB | 相对当前条目 3TFY | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 2OB0 Human MAK3 homolog in complex with Acetyl-CoA 提交 2006-12-18 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
2–169(168 aa)
|
非标准单体:是(mmCIF未提供具体位点) | ACO ACETYL COENZYME *A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
pH 7.5;298 K;Reservoir: 0.1 M Sodium acetate pH 5.0, 16% PEG3350, 10 mM DTT, 0.1% Dioxane. Protein: 11.8 mg/mL + 3-fold molar excess of ACOA in 20 mM Hepes pH 7.5, 0.1 M NaCl, 2.5 % 1,2-propandiol, and 10 mM DTT. Cryo: 75% reservoir + 25% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 7.50
|
分辨率 1.80 Å R-free 0.204 |
| 2OB0 Human MAK3 homolog in complex with Acetyl-CoA 提交 2006-12-18 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
2–169(168 aa)
|
非标准单体:是(mmCIF未提供具体位点) | ACO ACETYL COENZYME *A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
pH 7.5;298 K;Reservoir: 0.1 M Sodium acetate pH 5.0, 16% PEG3350, 10 mM DTT, 0.1% Dioxane. Protein: 11.8 mg/mL + 3-fold molar excess of ACOA in 20 mM Hepes pH 7.5, 0.1 M NaCl, 2.5 % 1,2-propandiol, and 10 mM DTT. Cryo: 75% reservoir + 25% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 7.50
|
分辨率 1.80 Å R-free 0.204 |
| 2OB0 Human MAK3 homolog in complex with Acetyl-CoA 提交 2006-12-18 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
2–169(168 aa)
|
非标准单体:是(mmCIF未提供具体位点) | ACO ACETYL COENZYME *A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
pH 7.5;298 K;Reservoir: 0.1 M Sodium acetate pH 5.0, 16% PEG3350, 10 mM DTT, 0.1% Dioxane. Protein: 11.8 mg/mL + 3-fold molar excess of ACOA in 20 mM Hepes pH 7.5, 0.1 M NaCl, 2.5 % 1,2-propandiol, and 10 mM DTT. Cryo: 75% reservoir + 25% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 7.50
|
分辨率 1.80 Å R-free 0.204 |
| 2PSW Human MAK3 homolog in complex with CoA 提交 2007-05-07 | 构建体不同 突变/修饰不同 聚集状态不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
2–169(168 aa)
|
非标准单体:是(mmCIF未提供具体位点) | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;Reservoir: 0.1 M Sodium acetate pH 5.0, 16% PEG3350, 10 mM DTT, 0.1% Dioxane. Protein: 11.8 mg/mL + 3-fold molar excess of CoA in 20 mM HEPES pH 7.5, 0.1 M NaCl, 2.5% 1,2-Propanediol, and 10 mM DTT. Cryo: 75% Reservoir + 25% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
分辨率 2.10 Å R-free 0.265 |
| 2PSW Human MAK3 homolog in complex with CoA 提交 2007-05-07 | 构建体不同 突变/修饰不同 聚集状态不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
2–169(168 aa)
|
非标准单体:是(mmCIF未提供具体位点) | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;Reservoir: 0.1 M Sodium acetate pH 5.0, 16% PEG3350, 10 mM DTT, 0.1% Dioxane. Protein: 11.8 mg/mL + 3-fold molar excess of CoA in 20 mM HEPES pH 7.5, 0.1 M NaCl, 2.5% 1,2-Propanediol, and 10 mM DTT. Cryo: 75% Reservoir + 25% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
分辨率 2.10 Å R-free 0.265 |
| 2PSW Human MAK3 homolog in complex with CoA 提交 2007-05-07 | 构建体不同 突变/修饰不同 聚集状态不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
2–169(168 aa)
|
非标准单体:是(mmCIF未提供具体位点) | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;Reservoir: 0.1 M Sodium acetate pH 5.0, 16% PEG3350, 10 mM DTT, 0.1% Dioxane. Protein: 11.8 mg/mL + 3-fold molar excess of CoA in 20 mM HEPES pH 7.5, 0.1 M NaCl, 2.5% 1,2-Propanediol, and 10 mM DTT. Cryo: 75% Reservoir + 25% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
分辨率 2.10 Å R-free 0.265 |
| 4X5K Human NAA50 complex with coenzyme A and an acetylated peptide 提交 2014-12-05 | 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 A
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;298 K;0.2 M sodium formate, 20% PEG 3350
|
分辨率 2.49 Å R-free 0.255 |
| 6PPL Cryo-EM structure of human NatE complex (NatA/Naa50) 提交 2019-07-08 | 聚集状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 A
1–169(169 aa)
|
未记录 | ACO ACETYL COENZYME *A × 2 IHP INOSITOL HEXAKISPHOSPHATE × 1 |
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 7
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.02 Å |
| 6PW9 Cryo-EM structure of human NatE/HYPK complex 提交 2019-07-22 | 聚集状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric |
链 A
1–169(169 aa)
|
未记录 | IHP INOSITOL HEXAKISPHOSPHATE × 1 ACO ACETYL COENZYME *A × 1 |
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 7
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 4.03 Å |
| 6WF3 Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1) 提交 2020-04-03 | 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 A
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex
|
分辨率 2.29 Å R-free 0.243 |
| 6WF3 Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1) 提交 2020-04-03 | 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 B
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex
|
分辨率 2.29 Å R-free 0.243 |
| 6WF3 Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1) 提交 2020-04-03 | 实验环境不同 结构质量不同 | Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 C
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex
|
分辨率 2.29 Å R-free 0.243 |
| 6WF3 Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1) 提交 2020-04-03 | 实验环境不同 结构质量不同 | Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 D
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex
|
分辨率 2.29 Å R-free 0.243 |
| 6WF3 Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1) 提交 2020-04-03 | 实验环境不同 结构质量不同 | Assembly 5 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 E
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex
|
分辨率 2.29 Å R-free 0.243 |
| 6WF3 Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1) 提交 2020-04-03 | 实验环境不同 结构质量不同 | Assembly 6 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 F
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex
|
分辨率 2.29 Å R-free 0.243 |
| 6WF5 Crystal structure of human Naa50 in complex with a truncated cofactor derived inhibitor (compound 2) 提交 2020-04-03 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 A
1–169(169 aa)
|
未记录 | U44 (2R)-2-hydroxy-3,3-dimethyl-N-{3-oxo-3-[(2-sulfanylethyl)amino]propyl}butanamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Co-crystallization: Naa50 apo protein (14.3 mg/ml) was incubated with compound 2 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein:ligand complex
|
分辨率 2.04 Å R-free 0.274 |
| 6WF5 Crystal structure of human Naa50 in complex with a truncated cofactor derived inhibitor (compound 2) 提交 2020-04-03 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric |
链 B
1–169(169 aa)
|
未记录 | U44 (2R)-2-hydroxy-3,3-dimethyl-N-{3-oxo-3-[(2-sulfanylethyl)amino]propyl}butanamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;286.15 K;Co-crystallization: Naa50 apo protein (14.3 mg/ml) was incubated with compound 2 in a 1:3 molar ratio on ice for 60 min. Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein:ligand complex
|
分辨率 2.04 Å R-free 0.274 |
| 6WFG Crystal structure of human Naa50 in complex with an inhibitor (compound 3) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 U3V (2S)-N-[(2S)-3-[1-(3-tert-butyl-1-methyl-1H-pyrazole-5-carbonyl)piperidin-4-yl]-1-(methylamino)-1-oxopropan-2-yl]-6-oxopiperidine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;294.15 K;Soak of compound into CoA bound crystals. Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane
|
分辨率 2.16 Å R-free 0.253 |
| 6WFG Crystal structure of human Naa50 in complex with an inhibitor (compound 3) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 U3V (2S)-N-[(2S)-3-[1-(3-tert-butyl-1-methyl-1H-pyrazole-5-carbonyl)piperidin-4-yl]-1-(methylamino)-1-oxopropan-2-yl]-6-oxopiperidine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;294.15 K;Soak of compound into CoA bound crystals. Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane
|
分辨率 2.16 Å R-free 0.253 |
| 6WFG Crystal structure of human Naa50 in complex with an inhibitor (compound 3) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 E
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 U3V (2S)-N-[(2S)-3-[1-(3-tert-butyl-1-methyl-1H-pyrazole-5-carbonyl)piperidin-4-yl]-1-(methylamino)-1-oxopropan-2-yl]-6-oxopiperidine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;294.15 K;Soak of compound into CoA bound crystals. Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane
|
分辨率 2.16 Å R-free 0.253 |
| 6WFK Crystal structure of human Naa50 in complex with CoA and an inhibitor (compound 4a) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 U2J (4S)-1-methyl-N-{(3S,5S)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;294 K;Compound 4a soaked into crystals of Naa50+CoA. CoA co-crystals: Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane
|
分辨率 1.87 Å R-free 0.222 |
| 6WFK Crystal structure of human Naa50 in complex with CoA and an inhibitor (compound 4a) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 U2J (4S)-1-methyl-N-{(3S,5S)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;294 K;Compound 4a soaked into crystals of Naa50+CoA. CoA co-crystals: Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane
|
分辨率 1.87 Å R-free 0.222 |
| 6WFK Crystal structure of human Naa50 in complex with CoA and an inhibitor (compound 4a) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–169(169 aa)
|
未记录 | COA COENZYME A × 1 U2J (4S)-1-methyl-N-{(3S,5S)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;294 K;Compound 4a soaked into crystals of Naa50+CoA. CoA co-crystals: Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane
|
分辨率 1.87 Å R-free 0.222 |
| 6WFN Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4a) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–169(169 aa)
|
未记录 | ACO ACETYL COENZYME *A × 1 U2J (4S)-1-methyl-N-{(3S,5S)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5.77;294 K;Naa50 apo protein (13.0 mg/ml) was incubated with 4a and AcCoA in a 1:3:3 molar ratio on ice for 60 min. Reservoir solution containing 0.1 M Bis_tris, pH 5.77 and 21% w/v PEG 3350 was mixed 0.2ul:0.2ul with Naa50:4b:AcCoA complex
|
分辨率 1.07 Å R-free 0.201 |
| 6WFO Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4b) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–169(169 aa)
|
未记录 | ACO ACETYL COENZYME *A × 1 U3Y (4S)-1-methyl-N-{(3S,5R)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5.77;294 K;Naa50 apo protein (13.0 mg/ml) was incubated with 4b and AcCoA in a 1:3:3 molar ratio on ice for 60 min. Reservoir solution of 0.1 M Bis_tris, pH 5.77 and 24% w/v PEG 3350 was mixed 0.2ul:0.2ul with Naa50:4b:AcCoA complex
|
分辨率 1.85 Å R-free 0.240 |
| 6WFO Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4b) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–169(169 aa)
|
未记录 | ACO ACETYL COENZYME *A × 1 U3Y (4S)-1-methyl-N-{(3S,5R)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5.77;294 K;Naa50 apo protein (13.0 mg/ml) was incubated with 4b and AcCoA in a 1:3:3 molar ratio on ice for 60 min. Reservoir solution of 0.1 M Bis_tris, pH 5.77 and 24% w/v PEG 3350 was mixed 0.2ul:0.2ul with Naa50:4b:AcCoA complex
|
分辨率 1.85 Å R-free 0.240 |
| 6WFO Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4b) identified using DNA encoded library technology 提交 2020-04-03 | 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–169(169 aa)
|
未记录 | ACO ACETYL COENZYME *A × 1 U3Y (4S)-1-methyl-N-{(3S,5R)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5.77;294 K;Naa50 apo protein (13.0 mg/ml) was incubated with 4b and AcCoA in a 1:3:3 molar ratio on ice for 60 min. Reservoir solution of 0.1 M Bis_tris, pH 5.77 and 24% w/v PEG 3350 was mixed 0.2ul:0.2ul with Naa50:4b:AcCoA complex
|
分辨率 1.85 Å R-free 0.240 |
| 9F1B Mammalian ternary complex of a translating 80S ribosome, NAC and NatA/E 提交 2024-04-18 | 聚集状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 信息不足 异源复合物;蛋白 × 83 PDB 声明:89-meric |
链 DA
1–169(169 aa)
|
未记录 | MG MAGNESIUM ION × 420 ZN ZINC ION × 8 UNX UNKNOWN LIGAND × 306 IHP INOSITOL HEXAKISPHOSPHATE × 1 SPD SPERMIDINE × 30 SPM SPERMINE × 3 GTP GUANOSINE-5'-TRIPHOSPHATE × 1 |
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 7.4
cryo-EM玻璃化条件
冷冻剂 ETHANE-PROPANE
|
分辨率 3.01 Å |
| 9F1C Mammalian quaternary complex of a translating 80S ribosome, NAC, MetAP1 and NatA/E 提交 2024-04-18 | 聚集状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 信息不足 异源复合物;蛋白 × 84 PDB 声明:90-meric |
链 DA
1–169(169 aa)
|
未记录 | UNX UNKNOWN LIGAND × 277 MG MAGNESIUM ION × 420 GTP GUANOSINE-5'-TRIPHOSPHATE × 1 SPD SPERMIDINE × 30 SPM SPERMINE × 3 ZN ZINC ION × 8 IHP INOSITOL HEXAKISPHOSPHATE × 1 |
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 7.4
cryo-EM玻璃化条件
冷冻剂 ETHANE-PROPANE
|
分辨率 3.78 Å |
| 9F1D Mammalian quaternary complex of a translating 80S ribosome, NAC, MetAP1 and NatA/E-HYPK 提交 2024-04-18 | 聚集状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 蛋白–RNA 异源复合物;蛋白 × 85 PDB 声明:91-meric |
链 DA
1–169(169 aa)
|
未记录 | UNX UNKNOWN LIGAND × 295 SPD SPERMIDINE × 30 MG MAGNESIUM ION × 420 SPM SPERMINE × 3 GTP GUANOSINE-5'-TRIPHOSPHATE × 1 IHP INOSITOL HEXAKISPHOSPHATE × 1 ZN ZINC ION × 8 |
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 7.4
cryo-EM玻璃化条件
冷冻剂 ETHANE-PROPANE
|
分辨率 3.26 Å |
共 14 个其他 PDB 条目、30 个 assembly。 打开独立比较页并筛选聚集状态
查看构建体与数据证据
| UniProt名称 | NAA50_HUMAN |
| Isoform | — |
| PDB实体 | 1 |
| 链与序列区间 | 作者链 A; PDB构建体 1–169; UniProt 1–169 作者链 B; PDB构建体 1–169; UniProt 1–169 作者链 C; PDB构建体 1–169; UniProt 1–169 |